Pyridone derivatives having affinity for cannabinoid 2-type receptor
AssigneeShionogi & Co., Ltd.
InventorsYukio Tada, Yasuyoshi Iso, Kohji Hanasaki
Life of this patent
Estimating the term…
Abstract
It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): 1 wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(═O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.
Claims36
A pharmaceutical composition having a binding activity to the cannabinoid type 2 receptor which contains as an active ingredient a compound of the formula (I):
- 1025
- wherein R1 is hydrogen, halogen, cyano, formyl, acyl, carboxy, alkoxycarbonyl, optionally substituted carbamoyl, isothiocyanato, optionally substituted amino, hydroxy, alkoxy, alkylthio, alkenyloxy, alkynyloxy, alkylsulfinyl, alkylsulfonyl, nitro, or a group represented by the formula:
- —Y1—Y2—Y3—Ra wherein Y1 and Y3 each is independently single bond or optionally substituted alkylene;
- Y2 is single bond, —O—, —O—C(═O)—, —O—C(═O)—O—, —O—C(═O)—NRb—, —O—SO2—, —NRb—, —NRb—C(═O)—, —NRb—SO2—, —NRb—C(═NH)—, —NRb—C(═O)—O—, —NRb—C(═O)—NRb—, —NRb—C(═O)—NRb—SO2—, —NRb—C(═S)—, —NRb—C(═S)—NRb—, —NRb—SO2—NRb—, —NRb—C(═NH)—NRb—, —S—, —SO2—O—, —SO2—NRb—, —SO2—NRb—C(═O)—NRb—, —C(═O)—O—, —C(═O)—NRb—, —C(═O)—NRb—C(═O)—, —C(═O)—NRb—C(═S)—, —C(═S)—NRb—, —C(═S)—NRb—C(═O)—, —C(═NH)—NRb—, —C(═O)—, —C(═O)—NRb—C(═NRb)—, or —C(═O)—NRb—NRb—;
- Ra is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclic group, optionally substituted heterocyclic group, or acyl;
- Rb each is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclic group, optionally substituted heterocyclic group, acyl, hydroxy, or alkoxy;
- R2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halogen, cyano, formyl, acyl, carboxy, alkoxycarbonyl, optionally substituted carbamoyl, isothiocyanato, optionally substituted amino, hydroxy, alkoxy, alkylthio, alkenyloxy, alkynyloxy, alkylsulfinyl, alkylsulfonyl, nitro, or a group represented by the formula:
- —Y4—Rc wherein Y4 is single bond, —O—, —S—, —SO—, —SO2—, —NH—, —C(═O)—, —CH2—, —C(═O)—NH—, or —NH—C(═O)—;
- Rc is optionally substituted carbocyclic group or optionally substituted heterocyclic group;
- R3 and R4 each is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halogen, cyano, formyl, acyl, carboxy, alkoxycarbonyl, optionally substituted carbamoyl, isothiocyanato, optionally substituted amino, hydroxy, alkoxy, alkylthio, alkenyloxy, alkynyloxy, alkylsulfinyl, alkylsulfonyl, nitro or a group represented by the formula:
- —Y5—Rd wherein Y5is single bond, optionally substituted alkylene, alkenylene, alkynylene, —O—, —S—, —SO—, —SO2—, —NH—, —C(═O)—, —CH2—, —C(═O)—NH—E—, or —NH—C(═O)—;
- E is single bond or optionally substituted alkylene;
- Rd is optionally substituted carbocyclic group or optionally substituted heterocyclic group;
- R5is hydrogen, optionally substituted alkyl which may have heteroatom and/or unsaturated bond or a group represented by the formula:
- —Y6—Re wherein Y6 is single bond, optionally substituted alkylene, alkenylene, alkynylene, —O—, —S—, —SO—, —SO2—, —NH—, —C(═O)—, —CH2—, —C(═O)—NH—E—, or —NH—C(═O)—;
- E is single bond or optionally substituted alkylene;
- Re is optionally substituted carbocyclic group or optionally substituted heterocyclic group;
- or
- any one of combinations of R2 and R3, R3 and R4, and R4 and R5, taken together with the adjacent atoms form optionally substituted cyclic group which may have heteroatom and/or unsaturated bond;
- X is S or O;
- provided that the case wherein R3 and R4 taken together with the adjacent atoms form benzene ring di-substituted with alkoxy, and R5is hydrogen or methyl is excluded;
- a prodrug, a pharmaceutically acceptable salt or solvate thereof.
A library of compound of the formula (I):
- 1027
- wherein R1 is a group represented by the formula:
- —Y1—Y2—Y3—Ra wherein Y1 is single bond;
- Y3 is single bond or optionally substituted alkylene;
- Y2 is —C(═O)—NRb—;
- Ra is optionally substituted carbocyclic group or optionally substituted heterocyclic group;
- Rb is hydrogen;
- R2 is hydrogen;
- R3 and R4 taken together with adjacent atom form unsubstituted carbocyclic group (provided that the bond between carbon atom substituted with R3 and carbon atom substituted R4 is the double bond, and the other bonds between carbon atoms are single bond)
- R5 is C3 or more alkyl or a group represented by the formula:
- —Y6—Re wherein Y6 is optionally substituted alkylene;
- Re is optionally substituted aryl optionally substituted cycloalkyl or optionally substituted heteroaryl;
- X is S or O.
A library of compound of the formula (I):
- 1028
- wherein R1 is a group represented by the formula:
- —Y1—Y2—Y3—Ra wherein R1 is single bond;
- Y2 is —C(═O)—NRb—;
- Y3 is single bond or optionally substituted alkylene;
- Ra is optionally substituted carbocyclic group or optionally substituted heterocyclic group;
- Rb is hydrogen;
- R2 is hydrogen;
- R3 is a group represented by the formula:
- —Y5—Rd wherein Y5 is single bond;
- Rd is optionally substituted aryl optionally substituted cycloalkyl or optionally substituted heteroaryl;
- R4 is hydrogen or alkyl;
- R5 is C3 or more alkyl or a group represented by the formula:
- —Y6—Re wherein Y6 is optionally substituted alkylene;
- Re is optionally substituted aryl optionally substituted cycloalkyl or optionally substituted heteroaryl;
- X is S or O.
A library of compound of the formula (I):
- 1029
- wherein R1 is a group represented by the formula:
- —Y1—Y2—Y3—Ra wherein Y1 and Y3 are single bond;
- Y2 is —NRb—C(═O)—;
- Ra is optionally substituted carbocyclic group;
- Rb is hydrogen;
- R2 is hydrogen;
- R3 and R4each is independently alkyl;
- R5 is C3 or more alkyl;
- X is O.
A compound of the formula:
- 1030
- wherein Y is single bond, —NH—, —O—, or —(CH2)1-5—;
- Y2 is —C(═O)—NH— or —NH—C(═O)—;
- Y3 is single bond or optionally substituted alkylene;
- Ra is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heteroaryl or optionally substituted heterocyclic group;
- R5 is C3 or more alkyl or a group represented by the formula:
- —Y6—Re— wherein Y6 is alkylene;
- Re is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclic group;
- a prodrug, a pharmaceutically acceptable salt or solvate thereof.
A compound of the formula:
- 1031
- wherein R3 and R4 each is independently alkyl;
- Y2 is —C(═O)—NH— or —NH—C(═O)—;
- Y3 is single bond or optionally substituted alkylene;
- Ra is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heteroaryl or optionally substituted heterocyclic group;
- R5 is C3 or more alkyl or a group represented by the formula:
- —Y6—Re— wherein Y6 is alkylene;
- Re is optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclic group;
- a prodrug, a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.